doi: 10.1258/ebm.2012.012157, PMID: [DOI] [PubMed] [Google Scholar] 151
Tapering your dose slowlyfrom maintenance levels down to lower maintenance or microdose protocolsallows your appetite regulation system time to gradually adjust
Wegovy, the weight-loss formulation of semaglutide, was approved in 2021 for chronic weight management in adults with a BMI of 30 or higher, or those with a BMI of 27 or higher with at least one weight-related condition
S., Tucker, J
They have very similar effects on the body, such as increasing the amount of various neurotransmitters in the brain, such as dopamine and norepinephrine
However, patients should consult their prescribing clinician, trial team, or pharmacist before adding any new medication, as interactions and contraindications must be considered on an individual basis